Connect with us

Hi, what are you looking for?

Jewish Business News

Life science

Breakthrough in Parkinson’s Disease: Israeli Scientists Discover New Therapeutics

Ben-Gurion University Researchers are focusing on bringing their discovery closer to clinical application

Scientists at the Ben-Gurion University of the Negev have discovered that a promising therapeutics protein called BMP5/7 could slow down or even halt the progression of Parkinson’s disease (PD).

The findings were published in clinical neurology journal, Brain.

Parkinson’s disease affects 1 percent of the population over the age of 60 which is 10 million worldwide or over one million Americans. Approximately 60,000 people are diagnosed with PD each year in the U.S.

This disease causes tremors and severe movement impairment due to progressive degeneration of dopamine-producing brain cells. It is believed that the protein “alpha-synuclein,” present in all human brains, misfolds and forms toxic clumps in these cells, which causes the disease.

While current Parkinson’s disease therapies improve symptoms, they are not effective in advanced illness stages and, unfortunately, do not slow or cure the disease.

Dr. Claude Brodski, M.D., head of the BGU’s Laboratory for Molecular Neuroscience, discovered that BMP5/7 signaling in neurons was significantly reduced in dopamine-producing brain cells, which could contribute to Parkinson’s disease advancement.

Dr. Brodski said: “We found that BMP5/7 treatment can, in a mouse model, efficiently prevent movement impairments caused by the accumulation of alpha-synuclein and reverse the loss of dopamine-producing brain cells.”

“These findings,” Dr. Brodski added, “are very promising since they suggest that BMP5/7 could slow or stop Parkinson’s disease progression. Currently, we are focusing all our efforts on bringing our discovery closer to clinical application.”

BGN Technologies, Ben-Gurion University’s technology transfer company, has filed several patent applications covering this breakthrough discovery.

“There is a vast need for new therapies to treat Parkinson’s disease, especially in advanced stages of the disease,” Dr. Galit Mazooz Perlmuter, senior vice president of business development, bio-pharma at BGN Technologies, notes, “Dr. Brodski’s findings, although still in their early stages, offer a disease-modified drug target that will address this devastating condition. We are now seeking an industry partner for further development of this patent-pending invention.”

Photo by LonlyTaws / Pixabay



  1. Daniel A Murphy

    June 8, 2021 at 5:11 am

    My wife has Parkinsons and we would like to help in funding the reserch.

    Daniel A Murphy

    • editor

      August 22, 2021 at 9:11 pm

      Please call: Dr. Claude Brodski, M.D., head of the (Ben Gurion University of the Negev, Israel (BGU) Laboratory for Molecular Neuroscience

  2. Polly Melson

    July 18, 2021 at 8:00 pm

    I have Parkinson disease. Looking for treatment.

    • Editor

      August 22, 2021 at 9:09 pm

      Please call: Dr. Claude Brodski, M.D., head of the (Ben Gurion University of the Negev, Israel (BGU) Laboratory for Molecular Neuroscience

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...


The contract signed between the Israeli government and Pfizer shows clearly and unequivocally that this is a clinical study on humans - The agreement...


Now Platika joins and elite club of $10 billion plus Israeli firms.